Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients.
OBJECTIVE
High cholesterol absorption in the small intestine has been proposed to be a risk factor of atherosclerosis. In this study, we evaluated the effect of ezetimibe monotherapy on arterial stiffness in type 2 diabetic patients.


METHODS
Forty type 2 diabetes mellitus patients with high serum low-density lipoprotein cholesterol (LDL-C) were enrolled and treated with ezetimibe 10 mg/day for 6 months. HbA1c, serum lipids, remnant-like particle-cholesterol (RLP-C), serum lipoprotein lipase mass (LPL mass) and the cardio-ankle vascular index (CAVI) were measured before and after ezetimibe treatment.


RESULTS
After 6 months of ezetimibe treatment, significant decreases in LDL-C, RLP-C and CAVI were observed. In the group that achieved the LDL-C goal of <120 mg/dL after 6 months of ezetimibe treatment, the pretreatment CAVI was markedly high, and CAVI decreased significantly after ezetimibe treatment.


CONCLUSIONS
In type 2 diabetic patients, ezetimibe monotherapy may have the potential to ameliorate arterial stiffness in addition to lowering LDL-C and RLP-C.
Miyashita
Yoh
Y
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University, 564-1 Shimoshizu, Chiba, Japan. mumon@sf6.so-net.ne.jp
Endo
Kei
K
Saiki
Atsuhito
A
Ban
Noriko
N
Nagumo
Ayako
A
Yamaguchi
Takashi
T
Kawana
Hidetoshi
H
Nagayama
Daiji
D
Ohira
Masahiro
M
Oyama
Tomokazu
T
Shirai
Kohji
K
D000842:Ankle / Q000098:blood supply*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001158:Arteries / Q000503:physiopathology*; D001384:Azetidines / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D008074:Lipoproteins; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D002784:Cholesterol; D008071:Lipoprotein Lipase; D000069438:Ezetimibe